Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.

Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, Sugiyama S, Jinnouchi H, Waki M, Doi N, Horii M, Kawata H, Somekawa S, Soeda T, Uemura S, Saito Y; investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial.

Circ J. 2013;77(12):3023-8. Epub 2013 Sep 13.

2.

Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.

Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Sakuma M, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators.

J Cardiol. 2013 Sep;62(3):165-70. doi: 10.1016/j.jjcc.2013.03.015. Epub 2013 Jun 16.

3.

Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.

Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators.

Diabetes Care. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615.

4.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators.

JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. Erratum in: JAMA. 2009 May 13;301(18):1882. JAMA. 2012 Nov 14;308(18):1861.

PMID:
18997198

Supplemental Content

Loading ...
Support Center